T1	Participants 362 581	Four hundred sixty-nine assessable advanced cancer patients were randomized to (1) oral megestrol acetate 800 mg/d liquid suspension plus placebo, (2) oral dronabinol 2.5 mg twice a day plus placebo, or (3) both agents.
T2	Participants 583 781	ligible patients acknowledged that loss of appetite or weight was a problem and reported the loss of 5 pounds or more during 2 months and/or a daily intake of less than 20 calories/kg of body weight
T3	Participants 912 1034	megestrol acetate-treated patients reported appetite improvement and weight gain compared with dronabinol-treated patients
T4	Participants 1429 1494	among megestrol acetate-treated and combination-treated patients.
T5	Participants 1601 1699	with the exception of an increased incidence of impotence among men who received megestrol acetate
T6	Participants 1813 1868	advanced cancer patients compared with dronabinol alone
